Stealth BioTherapeutics Corp.

Reenie McCarthy is the Chief Executive Officer and a member of the Board of Stealth BioTherapeutics. Reenie is a 20+ year veteran of the investment team of Morningside, Stealth’s principal investor, with extensive experience working with private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic areas.

Brian Blakey is the Chief Business Officer of Stealth BioTherapeutics. He brings 30 years of pharmaceutical marketing, alliance development and operations experience to Stealth. Previously, Brian was the COO of Element Marketing Group and the Vice President of Commercial Development at Salutria (formerly AtheroGenics). He has held senior positions at other pharmaceutical companies, including GlaxoSmithKline. Brian holds a Doctor of Pharmacy degree from the University of Florida.

Jim Carr is the Chief Clinical Development Officer of Stealth BioTherapeutics. He brings over 20 years of industry experience in the areas of clinical development, medical affairs, lifecycle management, new product planning, and global marketing to Stealth. Previously, Jim was an Executive Director in the Global Cardiovascular Franchise at GlaxoSmithKline. Prior to GlaxoSmithKline, Jim held the role of Vice President of Clinical Development at Arca Biopharma. Jim’s educational background is a Doctor of Pharmacy degree from the University of Minnesota and post-graduate training in clinical cardiovascular pharmacology. Prior to joining the pharmaceutical industry, Jim was on the clinical faculty at the University at Buffalo-SUNY School of Pharmacy.

Henry Hess joined Stealth BioTherapeutics in 2011, and serves as its chief legal counsel. Henry brings more than 15 years of experience in providing business, transactional and legal advice to both public and private life science, healthcare and technology companies. Prior to joining Stealth, Henry worked as an attorney with the law firms of Jenner & Block and Tabet DiVito & Rothstein, where he advised clients on multiple areas of law and business. Henry holds a BA from The Ohio State University and a law degree from the University of Wisconsin.

Marty Redmon is Chief Research & Development Officer at Stealth BioTherapeutics. Marty has more than 25 years of experience in pharmaceutical R&D, operations, and project and functional line management. Prior to joining Stealth, he served as Senior Vice President of Research, Development and Technical Operations at Precision Dermatology, and has previously held pharmaceutical development positions at Eli Lilly, Focal, Sepracor, Praecis, and ArQule. He brings experience managing R&D and manufacturing organizations responsible for development of a broad range of therapeutics in a variety of dosage forms. Marty holds a BS in Chemical Engineering and a PhD in Pharmaceutical Sciences, both from the University of Kentucky.

Rob Weiskopf brings more than 25 years of financial experience to Stealth, including a strong background in public biotech company operations and reporting from his 12-year tenure at ArQule, where he most recently served as Chief Financial Officer and Treasurer from 2015 to 2019. Mr. Weiskopf previously held financial management positions at Aware, Inc., Lightbridge Corporation, Digital Equipment Corporation/Compaq and Ernst & Young LLP. He holds a B.S. and an M.S.B.A. from the University of Massachusetts at Amherst’s Isenberg School of Management.

Brian Hotchkiss is the Vice President, Business Development and Strategy of Stealth Biotherapeutics. He brings more than 15 years of experience in both large pharmaceutical (Pfizer) and smaller biotechnology companies. Over the course of his career Brian has held positions with increasing responsibility within the business development, new product planning and finance functions.  Brian has an undergraduate in chemical engineering from Cornell University, master’s degrees in chemical engineering and biology from the University of Iowa and Brown University respectively, and an MBA from the Darden School of Business at UVA.